| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ITCI Stock Overview
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States.
Intra-Cellular Therapies Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$57.90 |
| 52 Week High | US$66.00 |
| 52 Week Low | US$28.40 |
| Beta | 1.27 |
| 1 Month Change | -0.65% |
| 3 Month Change | -6.75% |
| 1 Year Change | 43.92% |
| 3 Year Change | 312.69% |
| 5 Year Change | 356.99% |
| Change since IPO | 479.00% |
Recent News & Updates
Intra-Cellular Therapies: A Dramatic Story
Intra-Cellular's atypical antipsychotic CAPLYTA has all the makings of a blockbuster. Now in its initial bipolar launch phase, CAPLYTA is succeeding on all three key leading indicators. Intra-Cellular's financial position is a work in process.
Shareholder Returns
| ITCI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 5.4% | 9.7% | 6.3% |
| 1Y | 43.9% | 13.7% | -18.8% |
Return vs Industry: ITCI exceeded the US Pharmaceuticals industry which returned 12.8% over the past year.
Return vs Market: ITCI exceeded the US Market which returned -18.4% over the past year.
Price Volatility
| ITCI volatility | |
|---|---|
| ITCI Average Weekly Movement | 9.7% |
| Pharmaceuticals Industry Average Movement | 11.7% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ITCI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ITCI's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 512 | Sharon Mates | https://www.intracellulartherapies.com |
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders.
Intra-Cellular Therapies Fundamentals Summary
| ITCI fundamental statistics | |
|---|---|
| Market Cap | US$5.46b |
| Earnings (TTM) | -US$303.50m |
| Revenue (TTM) | US$102.92m |
53.1x
P/S Ratio-18.0x
P/E RatioIs ITCI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ITCI income statement (TTM) | |
|---|---|
| Revenue | US$102.92m |
| Cost of Revenue | US$112.57m |
| Gross Profit | -US$9.64m |
| Other Expenses | US$293.86m |
| Earnings | -US$303.50m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.22 |
| Gross Margin | -9.37% |
| Net Profit Margin | -294.89% |
| Debt/Equity Ratio | 0% |
How did ITCI perform over the long term?
See historical performance and comparisonValuation
Is ITCI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ITCI?
Other financial metrics that can be useful for relative valuation.
| What is ITCI's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$5.46b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 45.8x |
| Enterprise Value/EBITDA | -15.5x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does ITCI's PB Ratio compare to its peers?
| ITCI PB Ratio vs Peers |
|---|
| Company | PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 11.7x | ||
RVNC Revance Therapeutics | 43.6x | 56.3% | US$1.1b |
ROIV Roivant Sciences | 1.7x | 17.0% | US$3.2b |
PRGO Perrigo | 1.1x | n/a | US$5.6b |
TLRY Tilray Brands | 0.4x | 26.4% | US$1.8b |
ITCI Intra-Cellular Therapies | 6.9x | 73.2% | US$5.5b |
Price-To-Book vs Peers: ITCI is good value based on its Price-To-Book Ratio (6.9x) compared to the peer average (11.7x).
Price to Earnings Ratio vs Industry
How does ITCI's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Book vs Industry: ITCI is expensive based on its Price-To-Book Ratio (6.9x) compared to the US Pharmaceuticals industry average (1.8x)
Price to Book Ratio vs Fair Ratio
What is ITCI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 6.9x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate ITCI's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of ITCI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ITCI ($57.9) is trading below our estimate of fair value ($367.64)
Significantly Below Fair Value: ITCI is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ITCI's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Intra-Cellular Therapies forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Future Growth Score
5/6Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
73.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ITCI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: ITCI is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ITCI is expected to become profitable in the next 3 years.
Revenue vs Market: ITCI's revenue (44.6% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: ITCI's revenue (44.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ITCI's Return on Equity is forecast to be low in 3 years time (19.1%).
Discover growth companies
Past Performance
How has Intra-Cellular Therapies performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-22.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ITCI is currently unprofitable.
Growing Profit Margin: ITCI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ITCI is unprofitable, and losses have increased over the past 5 years at a rate of 22.2% per year.
Accelerating Growth: Unable to compare ITCI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ITCI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.7%).
Return on Equity
High ROE: ITCI has a negative Return on Equity (-38.29%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Intra-Cellular Therapies's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ITCI's short term assets ($848.3M) exceed its short term liabilities ($59.1M).
Long Term Liabilities: ITCI's short term assets ($848.3M) exceed its long term liabilities ($16.8M).
Debt to Equity History and Analysis
Debt Level: ITCI is debt free.
Reducing Debt: ITCI had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ITCI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ITCI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Dividend
What is Intra-Cellular Therapies's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ITCI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ITCI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ITCI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ITCI's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ITCI has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
3.8yrs
Average management tenure
CEO
Sharon Mates (68 yo)
20.08yrs
Tenure
US$7,245,943
Compensation
Dr. Sharon Mates, Ph D., co-founded Intra-Cellular Therapies, Inc. (a/k/a ITI) in May 2002 and has been its Chairman, President and Chief Executive Officer since June 2002. Earlier in her career, Dr. Mates...
CEO Compensation Analysis
Compensation vs Market: Sharon's total compensation ($USD7.25M) is about average for companies of similar size in the US market ($USD8.23M).
Compensation vs Earnings: Sharon's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: ITCI's management team is considered experienced (3.8 years average tenure).
Board Members
Experienced Board: ITCI's board of directors are considered experienced (8.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.2%.
Top Shareholders
Company Information
Intra-Cellular Therapies, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Intra-Cellular Therapies, Inc.
- Ticker: ITCI
- Exchange: NasdaqGS
- Founded: 2002
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$5.461b
- Shares outstanding: 94.32m
- Website: https://www.intracellulartherapies.com
Number of Employees
Location
- Intra-Cellular Therapies, Inc.
- 430 East 29th Street
- New York
- New York
- 10016
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/06/27 00:00 |
| End of Day Share Price | 2022/06/27 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.